|
pharma (3)
With only 4 weeks left until the Life Sciences Internal Audit Conference, February 8-9, 2012 in Philadelphia, PA, don’t miss out on your opportunity to attend the event!
Join key speakers, including:
Andy Weintraub, Director, Group Internal Audit at AstraZeneca
David Bolton, Internal Audit Manager at Biomet, Inc.
Tami McLaine, Director, Audit at Baxter International
Katie McCormick, Senior Manager, Corporate Analysis & Control at Boston Scientific Corporation
Jeffrey Antoon, Director, Corporate
Executive Summary: Sometimes your reputation in the industry is everything for you. Reputation is sacrosanct and hence any risk to the reputation of the company is considered high
I worked at Sony for many years. For a company such as Sony, the brand reputation is sacrosanct. Which means any incident or event which will bring bad name to the company will be considered a “high” risk event. This is much more accentuated because the company is Japanese .
For example a pharma company makes a mistake w
